30-day average of 13 articles ยท scale โ100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cigna news is Somewhat Bullish (+35)
on a scale from โ100 to +100.
That is down 7 points from the previous 30 days (+42).
๐ข CI operates via Cigna Healthcare and Evernorth Health Services segments.
โ ๏ธ CI faces 2027 headwinds like declining pharmacy membership and ACA exit.
Somewhat Bullish +45
Is Wall Street Bullish or Bearish on Cigna Group Stock?
AI-generated analysis
Key insights
๐ข Cigna Group operates through two main segments: Cigna Healthcare providing medical and insurance solutions, and Evernorth Health Services focusing on pharmacy benefits and drug distribution.
๐ Stock performance has underperformed benchmarks, with shares up 9.5% over the past 52 weeks versus the S&P 500's 10.8% gain and trailing the IHF Healthcare ETF by 14 percentage points.
โ ๏ธ Management identified specific 2027 headwinds including declining pharmacy membership, weaker pharmacy benefit earnings, ACA market exit, and a slower specialty drug pipeline.
๐ The company has maintained a track record of beating consensus EPS estimates in each of the past four quarters despite mixed stock price action.
๐ฅ Analyst consensus is a 'Moderate Buy' with 14 'Strong Buy' ratings out of 23 covers, indicating overall bullish sentiment from Wall Street.
๐ฐ Wells Fargo raised its price target to $325 while maintaining an 'Equal Weight' rating, reflecting a nuanced view on the stock's prospects.
๐ฏ The mean analyst price target of $347.17 implies 17.2% upside potential relative to the current share price as of publication.
๐ Cigna has successfully upgraded its full-year outlook, providing support for the stock despite recent volatility following Q3 earnings.
๐ Bullish signals
๐Cigna has surpassed consensus EPS estimates in each of the past four quarters, demonstrating a steady track record of delivering stronger-than-expected results.
๐ The company recently upgraded its full-year outlook, providing fundamental support for the stock despite recent price volatility.
๐ฅAnalyst consensus is a 'Moderate Buy' with 14 out of 23 ratings classified as 'Strong Buy', indicating strong institutional confidence.
๐ Risk factors
๐ Shares slipped following Q3 results on November 5, even though the company beat revenue and earnings estimates, signaling investor concern about future guidance.
โ ๏ธManagement explicitly flagged declining pharmacy membership and weaker pharmacy benefit earnings as significant challenges for 2027.
Article
Cigna Group (CI), a global healthcare company with a market cap of approximately $79.4 billion, operates through Cigna Healthcare and Evernorth Health Services. The business serves over 185 million customer relationships across more than 30 markets, offering medical, dental, behavioral health, and insurance solutions alongside pharmacy benefits and drug distribution services.
Despite strong operational fundamentals including repeated Wall Street beats and an upgraded full-year outlook, Cigna's stock performance has lagged the broader market. Shares have risen 9.5% over the past 52 weeks compared to the S&P 500's 10.8% gain, and the company trails its healthcare peers significantly in 2026 year-to-date returns.
Following Q3 results on November 5, where shares slipped despite beating revenue and earnings estimates, investors are concerned about headwinds facing the company in 2027. Management has specifically flagged declining pharmacy membership, weaker pharmacy benefit earnings, an exit from the ACA market, and a slower specialty drug pipeline as key challenges ahead.
Analyst sentiment remains cautiously positive with a consensus 'Moderate Buy' rating based on 23 covers. Wells Fargo recently raised its price target to $325, while the average analyst price target of $347.17 implies a 17.2% premium to current levels, suggesting potential upside despite near-term operational concerns.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cigna Group stock closed at approximately USD 275 on September 18, 2026, trading near the mid-USD 270s as of September 19. The company carries a consensus rating of Moderate Buy among 23 analysts, with an average price target of USD 337.10 implying roughly 22% upside from current levels. Additional data from Simply Wall St suggests an average one-year target near USD 340.50 across 24 analysts, reinforcing the view that shares are undervalued relative to fundamental assessments.
Valuation metrics highlight Cigna Group trading at a forward price-to-earnings ratio of 8.47, significantly below the industry average of 15.27, representing a discount of about 44%. Consensus estimates for 2026 earnings peg per-share growth at 2.3% to USD 30.51. The stock's market capitalization is approximately USD 72.77 billion, with the current price situated near the middle of its 52-week trading range between USD 239.51 and USD 315.47.
Strategically, Cigna Group is leveraging artificial intelligence across its health services platform to manage rising healthcare costs, though recent performance has lagged peers with a six-month gain of 4.3% versus an industry increase of 36.4%. While analysts emphasize solid underlying earnings power and cash-flow profiles supporting potential total returns, the stock faces competitive and regulatory risks inherent in the managed-care landscape. The path to re-rating depends on execution in AI-enabled care management and cost control.
Investors note that the combination of a discounted earnings multiple, double-digit implied upside relative to consensus targets, and Cigna's dividend and buyback policies may appeal to value-oriented strategies. However, divergent analyst ratings, including a Hold from Zacks Investment Research alongside Moderate Buy consensus, indicate mixed opinions on growth prospects versus policy risks. The near-term debate centers on whether the market is pricing in sufficient caution regarding growth and regulatory developments.
๐ Cigna trades at $275 with $337.10 analyst target implying 22% upside.
๐ Stock trades at forward P/E of 8.47, roughly 44% below industry average.
๐ค Deploying AI across health services to help rein in rising healthcare costs.
๐ Shares rose 4.3% over six months, lagging peer group's 36.4% growth.
Cigna Group (CI) is integrating artificial intelligence into its healthcare operations to address elevated medical costs and improve care coordination. The company utilizes AI-driven insights alongside clinical expertise to identify complex health needs, such as cancer and heart disease, earlier in their progression. This proactive approach aims to guide members toward appropriate care before conditions worsen, potentially reducing the need for costly interventions.
The expanded AI-enabled capabilities are projected to reach 20% more customers with emerging complex health needs. Participants in these programs have demonstrated reduced medical costs of approximately $2,000 annually on average, while early engagement has contributed to a 42% reduction in avoidable inpatient stays. Additionally, Cigna is applying AI to specialty pharmacy through its Pharmacy Forward program, which aims to shorten the time between prescription and treatment by half.
Despite these technological advancements, Cigna faces ongoing industry-wide cost pressures. The company reported elevated medical cost trends in the second quarter of 2026, with management expecting similar trends to continue through 2027. Consequently, its Medical Cost Ratio (MCR) deteriorated by 130 basis points year over year. While AI offers additional tools for managing costs and improving access, it is not viewed as a standalone solution to resolve the broader industry's financial challenges.
From an investment perspective, Cigna shares have risen 4.3% over the past six months, significantly outpacing the industry's growth of 36.4%. The stock currently trades at a forward price-to-earnings ratio of 8.47, which is below the industry average of 15.27, and carries a Zacks Value Score of A. Analysts estimate Cigna's 2026 earnings at $30.51 per share, implying a 2.3% growth from the prior year.
๐ค Cigna expands AI to identify health needs earlier and guide care.
๐ AI programs reach 20% more customers with complex health needs.
๐ฐ AI participants reduce medical costs by about $2,000 annually.
๐ฅ Early AI engagement cuts avoidable inpatient stays by 42%.
โ ๏ธ Q2 2026 medical cost trend remained elevated with MCR deterioration.
๐ค Cigna is expanding AI usage to identify emerging health needs earlier and guide members toward appropriate care.
๐ AI-enabled programs are expected to reach 20% more customers with complex health needs.
๐ฐ Participants in Cigna's AI programs have reduced medical costs by about $2,000 annually on average.
๐ฅ Early engagement via AI has contributed to a 42% reduction in avoidable inpatient stays.
๐ The Pharmacy Forward initiative uses AI to cut average time to therapy by half.
โก AI is reducing clinicians' documentation time by as much as 50% in specialty pharmacy.
๐ CI shares have risen 4.3% over the past six months compared with the industry's growth of 36.4%.
๐ต Cigna trades at a forward P/E ratio of 8.47, below the industry average of 15.27.
๐ The company carries a Zacks Value Score of A and a Zacks Rank #3 (Hold).
โ ๏ธ CI's medical cost trend remained elevated in Q2 2026 with an MCR deterioration of 130 basis points.
Bullish Signals
AI care coordination reaches 20% more complex customers.
AI programs cut medical costs by $2,000 annually.
Early AI engagement reduces inpatient stays by 42%.
Pharmacy Forward initiative halves time to therapy.
AI cuts clinician documentation time by up to 50%.
Risk Factors
Medical cost trend remained elevated in Q2 2026.
Elevated trends expected through 2026 and 2027.
MCR deteriorated 130 bps year over year.
Bullish Signals
Cigna's AI-enabled care coordination is projected to reach 20% more customers with emerging complex health needs.
Customers participating in AI programs have reduced medical costs by about $2,000 annually on average.
Early engagement through AI has contributed to a 42% reduction in avoidable inpatient stays.
The Pharmacy Forward initiative aims to cut average time to therapy by half using AI.
AI efforts are reducing clinicians' documentation time by as much as 50%.
CI shares have risen 4.3% over the past six months, outperforming the broader industry growth of 36.4%.
Risk Factors
Cigna's medical cost trend remained elevated in the second quarter of 2026.
Management expects elevated medical cost trends to continue through 2026 and 2027.
The company's Medical Cost Ratio (MCR) deteriorated by 130 basis points year over year.
Cigna Group CEO Brian C. Evanko filed a Form 4 on September 2, 2026, disclosing equity awards granted to him on September 1, 2026. The filing details the receipt of 3,113 shares of restricted common stock and an employee stock option for 6,716 shares.
The restricted stock award was issued at no cost with a vesting schedule spanning three equal annual installments beginning September 1, 2027. Following this transaction, Evanko's direct beneficial ownership of Cigna Group common stock stands at 41,030 shares.
Additionally, the CEO holds indirect beneficial interests totaling approximately 26,533 shares through a Grantor Retained Annuity Trust and the company's 401(k) plan. The granted stock option allows for the purchase of shares at an exercise price of $281.1325 per share, expiring in September 2037.
๐ Cigna CEO filed Form 4 for equity grants on Sept 1, 2026.
๐ Received 3,113 restricted stock shares with three-year vesting starting 2027.
๐ Holds direct beneficial ownership of 41,030 Cigna common stock shares.
๐ Granted options for 6,716 shares at $281.13 exercise price expiring in 2036.
๐ฆ Indirect holdings include 25,614 shares via GRAT and 919 via 401(k).
๐ Cigna Group CEO Brian C. Evanko filed a Form 4 on September 2, 2026, detailing equity grants made on September 1, 2026.
๐ He received a restricted stock award of 3,113 shares of common stock issued at no cost with a three-year vesting schedule starting in 2027.
๐ Evanko now holds direct beneficial ownership of 41,030 shares of Cigna Group common stock following the transaction.
๐ An employee stock option for 6,716 shares was granted with an exercise price of $281.1325 and a ten-year expiration date.
๐ฆ The filing confirms Evanko's indirect holdings include approximately 25,614 shares held via a GRAT and 919 shares through the company 401(k) plan.
Bullish Signals
CEO Evanko increased ownership to 41,030 shares via 3,113 new grants.
Equity awards align pay with long-term shareholder value.
Bullish Signals
CEO Brian C. Evanko increased his direct beneficial ownership of common stock to 41,030 shares following the grant of 3,113 restricted shares.
The receipt of equity awards aligns executive compensation with long-term shareholder value and retention goals for Cigna Group.
Cigna Group (CI) stock is trading near recent highs around USD 299.27, supported by a moderate buy consensus and an average 12-month price target of approximately USD 339.45 as of September 7, 2026. Analysts maintain this positive stance based on the company's latest reported financial results, which included multi-billion-dollar revenue and solid earnings per share growth compared to the prior-year quarter.
The company delivered mid-single-digit percentage revenue growth driven by premium expansion and affiliated health services revenue. Earnings per share increased further due to disciplined cost control and active share repurchases that reduced the share count. Management provided full-year 2026 guidance for EPS growth with operating margins expected to remain stable despite ongoing medical cost pressures.
Cigna Group's valuation relies heavily on its ability to manage medical loss ratios within guided ranges and leverage its scale in health services and pharmacy benefit businesses. The company's diversified portfolio includes high-margin health services that help offset traditional insurance line pressures, supporting overall profitability and capital returns via dividends and buybacks. However, investors must monitor regulatory changes in Medicare Advantage and employer-sponsored plans, as well as potential medical cost inflation that could impact margins.
๐ Cigna stock trades at $299.27 with 13% upside to $339.45 consensus target.
๐ Mid-single-digit revenue growth and rising EPS driven by cost control and buybacks.
โ๏ธ Regulatory uncertainty in Medicare Advantage poses key risk to future profitability.
๐ก๏ธ Health services portfolio provides high-margin revenue to offset traditional insurance pressures.
๐ Cigna Group stock trades at approximately USD 299.27 with an implied upside of roughly 13% toward the consensus 12-month price target of USD 339.45.
๐ The company reported mid-single-digit revenue growth and rising earnings per share supported by disciplined cost control and share repurchases in its latest quarter.
๐ผ Institutional investor HighTower Advisors LLC increased its position in Cigna Group, signaling continued confidence in the insurer's long-term fundamentals.
๐ก๏ธ Management guidance calls for full-year 2026 EPS growth with operating margins expected to remain broadly stable despite medical cost trends.
โ๏ธ Analysts highlight regulatory uncertainty regarding Medicare Advantage and employer-sponsored plans as a key risk that could affect future profitability.
๐ฅ Cigna's health services portfolio, including pharmacy benefit management, provides high-margin revenue to offset pressures in traditional insurance lines.
๐ Medical cost inflation remains a critical watchpoint; claims trends running above pricing models could force lower margins or premium adjustments.
๐ฐ The company continues to return capital to shareholders through dividends and share repurchases, reinforcing its status as a large-cap managed care leader.
Bullish Signals
Stock trades at $299.27 with $339.45 analyst target, implying 13% upside.
Delivered mid-single-digit revenue growth and rising EPS driven by premium expansion.
HighTower Advisors increased position, reflecting confidence in long-term fundamentals.
Projects full-year 2026 EPS growth with stable operating margins.
Health services portfolio generates high-margin revenue supporting profitability.
Risk Factors
US healthcare reforms pose meaningful profitability uncertainties.
Medical cost inflation risks higher loss ratios.
Reimbursement adjustments could pressure margins.
Bullish Signals
Cigna Group stock trades at USD 299.27 with an average analyst price target of USD 339.45, implying roughly 13% upside potential if the stock reaches consensus valuations.
The company delivered mid-single-digit revenue growth and rising earnings per share in its most recent quarter, driven by premium expansion and disciplined cost control.
Institutional investor HighTower Advisors LLC increased its position in Cigna Group, reflecting professional money managers' confidence in the company's long-term fundamentals.
Management guidance projects full-year 2026 EPS growth with operating margins expected to remain stable, providing a clear path for shareholder value creation.
Cigna's health services portfolio generates high-margin revenue that helps offset pressures in traditional insurance lines and supports overall profitability.
Risk Factors
Regulatory changes in the US healthcare system, including potential reforms to Medicare Advantage and employer-sponsored plans, pose meaningful uncertainties for future profitability.
Medical cost inflation remains a significant risk; if claims trends exceed pricing models, Cigna may face higher medical loss ratios or be forced to adjust premiums.
Adjustments to reimbursement formulas or tightened oversight of pharmacy benefit management practices could pressure margins and challenge current growth assumptions.
This article compares CVS Health (NYSE: CVS) and Cigna Group (NYSE: CI) as potential holdings for retirement portfolios, highlighting that both are currently trading at historically low valuations. Cigna is noted for being cheaper on key metrics, trading at approximately 9.4x trailing adjusted earnings compared to CVS's 11.3x. The analysis emphasizes Cigna's superior earnings quality, citing a 73.47% year-over-year net income growth in FY2025 to $5.957 billion, whereas CVS saw its net income fall 62.55% due to significant goodwill impairment and litigation charges.
Cigna demonstrated consistent execution by beating adjusted EPS estimates in all four quarters of 2025, with its specialty care engine, Evernorth Health Services, posting 17% revenue growth in Q4. The company also aggressively returned capital through share repurchases, buying back 11.9 million shares for roughly $3.6 billion in 2025. In contrast, CVS showed mixed results with growing pharmacy revenue but a sharp 45.28% decline in operating income and a reduction of its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion.
The piece concludes that while CVS offers a higher dividend yield approaching 3.5% suitable for income-focused retirees, Cigna is positioned as the stronger long-term wealth builder over a 10-to-15-year horizon. Over the past decade, Cigna has compounded returns at 101.36%, significantly outperforming CVS's 1.84%. The author suggests that while CVS requires stabilization in its Health Care Benefits segment, Cigna continues to demonstrate consistent operational discipline and capital efficiency.
๐ CI trades at lower valuation multiple of 9.4x vs CVS's 11.3x.
๐ CI net income grew 73.47% YoY to $5.957 billion in FY2025.
๐ CI beat adjusted EPS estimates in all four quarters of 2025.
๐ CI Evernorth Health Services posted 17% revenue growth in Q4 2025.
๐ CI repurchased 11.9 million shares for $3.6 billion in 2025.
๐ Cigna trades at a lower valuation multiple of approximately 9.4x trailing adjusted earnings compared to CVS's 11.3x.
๐ Cigna reported strong financial performance with net income growing 73.47% year-over-year in FY2025 to $5.957 billion.
๐ CVS experienced a significant decline in profitability, with net income falling 62.55% due to a $5.7 billion goodwill impairment and litigation charges.
๐ Cigna achieved consistent execution by beating adjusted EPS estimates in all four quarters of 2025.
๐ Cigna's specialty care engine, Evernorth Health Services, posted 17% revenue growth in Q4 2025 with pharmacy customers expanding to 123.6 million.
๐ Cigna aggressively returned capital by repurchasing 11.9 million shares for approximately $3.6 billion in 2025.
๐ฐ CVS offers a higher dividend yield approaching 3.5% with an annualized payout of $2.66, appealing to income-focused investors.
๐ CVS operating income fell 45.28% year-over-year despite growth in same-store prescription volume and pharmacy revenue.
๐ CVS reduced its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion.
๐ Cigna has delivered superior long-term performance, compounding returns of 101.36% over the past decade versus CVS's 1.84%.
Bullish Signals
Net income surged 73.47% YoY to $5.957B in FY2025.
Beat adjusted EPS estimates in all four quarters of 2025.
Evernorth Health Services achieved 17% revenue growth in Q4 2025.
Repurchased 11.9 million shares for $3.6 billion during 2025.
SG&A ratio improved to 5.0% from 5.9% year-over-year.
Risk Factors
Trades at 9.3x vs CVS's 10.7x, limiting upside if healthcare re-rates.
Bullish Signals
Cigna demonstrated exceptional earnings quality with net income surging 73.47% year-over-year in FY2025 to reach $5.957 billion.
The company maintained a perfect track record of beating adjusted EPS estimates in all four quarters of 2025, showing consistent execution.
Cigna's specialty care engine, Evernorth Health Services, achieved 17% revenue growth in Q4 2025 while expanding its pharmacy customer base to 123.6 million.
Management aggressively returned capital to shareholders by repurchasing 11.9 million shares for approximately $3.6 billion during 2025.
Cigna improved its SG&A ratio to 5.0% from 5.9% year-over-year, indicating better operational efficiency and cost control.
The stock has delivered robust long-term performance with a total return of 101.36% over the past decade compared to CVS's minimal growth.
Risk Factors
The company trades at a forward multiple of roughly 9.3x against CVS's 10.7x, which may limit upside if the market re-rates healthcare valuations higher.
Cigna Group reported quarterly earnings of $7.78 per share on July 30, 2026, beating the consensus estimate of $7.60. The company generated revenue of $70.04 billion for the quarter, representing a 6.7% increase year-over-year, though this figure was marginally below analyst expectations of $70.14 billion. Despite operating in a sector with typically thin margins, Cigna achieved a net margin of 2.27% and a return on equity of 19.75%, highlighting the profitability of its integrated health services and insurance model.
Guidance for fiscal 2026 remains firm at $30.45 per share, which aligns closely with the average analyst forecast of $30.51. This reaffirmation suggests that the company's recent quarterly performance is tracking well toward its full-year targets, providing investors with clear visibility into earnings for the remainder of 2026. The stock currently trades at approximately $282.24, which is below the consensus price target of $339.45, indicating potential upside according to analyst ratings.
Cigna Group continues to return capital to shareholders through a quarterly dividend of $1.56 per share, resulting in an annualized yield of roughly 2.2% at current prices. The payout ratio stands at approximately 25.82%, reflecting a sustainable approach to dividends relative to earnings. While the company's large revenue base provides scale, analysts note that modest net margins mean that shifts in medical cost trends or utilization rates could significantly impact future net income and per-share earnings.
๐ CI beat EPS estimates at $7.78 despite revenue missing expectations.
๐ฐ Revenue grew 6.7% YoY to $70.04 billion.
๐ฏ Fiscal 2026 EPS guidance reaffirmed at $30.45.
๐ต Quarterly dividend of $1.56 yields ~2.2%.
๐ Stock trades below analyst price target of $339.45.
๐ Cigna Group delivered quarterly EPS of $7.78, beating the consensus estimate of $7.60.
๐ฐ Revenue reached $70.04 billion, marking a 6.7% year-over-year increase despite being slightly below analyst expectations.
๐ The company reported a net margin of 2.27% and a return on equity of 19.75% for the latest quarter.
๐ฏ Fiscal 2026 EPS guidance was reaffirmed at $30.45, aligning closely with the average analyst forecast of $30.51.
๐ต Cigna Group pays a quarterly dividend of $1.56, yielding approximately 2.2% on the current share price.
๐ The stock trades at $282.24, which is significantly below the consensus analyst price target of $339.45.
๐ข Cigna operates through integrated health services and insurance segments serving employers, government programs, and individuals.
โ ๏ธ Analysts warn that small shifts in medical cost trends or utilization could materially impact net income due to thin margins.
Bullish Signals
Cigna Group beat quarterly earnings expectations with EPS of $7.78 versus the consensus estimate of $7.60.
The company reaffirmed its fiscal 2026 EPS guidance at $30.45, which is broadly in line with analyst forecasts, providing strong earnings visibility.
Cigna Group maintains a sustainable dividend payout ratio of approximately 25.82% while returning cash via a quarterly dividend of $1.56 per share.
Analysts see significant upside potential as the current stock price of $282.24 is well below the consensus price target of $339.45.
Risk Factors
Cigna Group's quarterly revenue of $70.04 billion was marginally below analyst expectations of $70.14 billion.
The company operates with relatively thin net margins of 2.27%, making it sensitive to shifts in medical cost trends, pricing, or utilization rates.
Cigna Group (CI) reported that its President and Chief Executive Officer, Brian C. Evanko, received new equity awards on September 1, 2026. The compensation package included the grant of 6,716 stock options with an exercise price of $281.1325 per share and a separate award of 3,113 restricted shares of common stock.
Both the stock options and the restricted shares are scheduled to vest in three equal annual installments beginning September 1, 2027. Following these grants, Evanko holds 41,030 common shares directly, plus indirect holdings of 25,614 shares through a GRAT and 919.5791 shares through the company's 401(k) Plan.
The filing indicates that no Rule 10b5-1 trading plan was in place for these transactions. These equity grants align executive incentives with long-term shareholder value, though they represent future dilution potential upon option exercise and add to the insider ownership structure of the insurer.
๐ Cigna CEO Brian Evanko received new equity awards on Sept 1, 2026.
๐ Granted 6,716 options at $281.13/share and 3,113 restricted shares.
โณ All awards vest in three equal annual installments starting Sept 1, 2027.
๐ผ Evanko holds 41,030 common shares directly plus indirect holdings post-grant.
๐ซ No Rule 10b5-1 trading plan was used for these specific transactions.
๐ Cigna Group CEO Brian C. Evanko received new equity awards on September 1, 2026.
๐ He was granted 6,716 stock options with an exercise price of $281.1325 per share.
๐ A separate award of 3,113 restricted shares was also granted to the CEO.
โณ Both the options and restricted shares vest in three equal annual installments starting September 1, 2027.
๐ผ After the grants, Evanko holds 41,030 common shares directly and additional indirect holdings.
๐ซ The filing confirms no Rule 10b5-1 trading plan was used for these specific transactions.
Bullish Signals
Cigna granted significant equity compensation to CEO.
Grant of 6,716 options creates future shareholder dilution risk.
Restricted shares have a three-year vesting lock-up period.
Bullish Signals
Cigna Group has granted significant equity compensation to its CEO, aligning executive interests with long-term shareholder performance and retention goals.
The substantial increase in insider ownership demonstrates management's confidence in the company's future prospects and commitment to retaining top leadership.
Risk Factors
The grant of 6,716 stock options represents a potential source of future dilution for existing shareholders upon exercise.
The restricted shares are subject to a three-year vesting schedule, limiting immediate liquidity and creating a lock-up period for the insider.
Cigna Group director George Kurian reported an acquisition of 108.6642 phantom stock units on August 31, 2026, under the company's Deferred Compensation Plan of 2005 for Directors. This transaction involved a voluntary deferral of a portion of his cash retainer into a hypothetical stock fund, with an additional 10.7387 units acquired via the plan's dividend reinvestment feature.
The reported acquisition increased Kurian's directly held phantom stock balance to a total of 2,041.8523 units. Each unit is economically equivalent to one share of Cigna Group's common stock but will be settled in cash rather than issuing actual shares, thereby avoiding immediate share dilution while aligning the director's compensation with the firm's stock performance.
The filing indicates that the transaction was not executed under a Rule 10b5-1 trading plan. This insider activity highlights the company's use of phantom stock units as a retention and incentive tool for its board, linking executive deferred compensation directly to the market value of Cigna's equity without altering the share count.
๐ Director George Kurian acquires 108.6642 phantom units, raising total holdings to 2,041.8523.
๐ฐ Purchase defers cash retainers and includes 10.7387 units from dividend reinvestment.
๐ Phantom units match common share value but settle in cash without dilution.
โ๏ธ Form 4 filing confirms no participation in a Rule 10b5-1 trading plan.
๐ข Transaction aligns director incentives with Cigna shareholder value growth.
๐ Cigna director George Kurian acquired 108.6642 phantom stock units on August 31, 2026, increasing his total direct holdings to 2,041.8523 units.
๐ฐ The acquisition represents a voluntary deferral of cash retainer payments and includes 10.7387 units from dividend reinvestment under the 2005 Deferral Plan.
๐ Each phantom unit is economically equivalent to one Cigna common share but settles in cash, avoiding immediate equity dilution for the company.
โ๏ธ The transaction was filed on a Form 4 and explicitly does not affirm participation in a Rule 10b5-1 trading plan.
๐ข This filing illustrates Cigna's use of hypothetical stock funds to align director incentives with shareholder value growth.
Bullish Signals
Phantom stock links director pay to share price.
Director retention avoids immediate equity dilution.
Bullish Signals
Cigna utilizes phantom stock units under its Deferred Compensation Plan to incentivize directors, linking their deferred cash retainers directly to the company's share price performance.
The acquisition of 108.6642 units via retainer deferral and dividend reinvestment demonstrates strong director alignment with long-term shareholder value without causing immediate equity dilution.
Cigna Group (CI) has delivered a 41.0% total return over the past five years, positioning it as a steady compounder despite recent muted short-term returns. The company is currently trading at a P/E ratio of approximately 11.5x, which stands in stark contrast to the broader Healthcare industry average of 25.0x and peer group average of 31.6x.
Simply Wall St analysis indicates that Cigna Group screens as undervalued based on market multiples, with a high value score suggesting the stock is cheap relative to its current earnings power. The Fair Ratio model estimates a reasonable P/E multiple of 28.7x, highlighting a significant valuation gap between the current market price and sector benchmarks.
Investors are evaluating whether the recent share price decline offers a reasonable entry point for those focused on fundamental value. While the launch of new products like Connected Benefits aims to drive engagement in Cigna Healthcare, ongoing regulatory scrutiny regarding its pharmacy benefit model presents potential risks that could pressure margins and investor sentiment.
๐ CI returned 41% over five years as a steady compounder.
๐ CI trades at 11.5x P/E, well below industry average of 25x.
๐ High value score of 6 indicates CI is broadly undervalued.
๐ก Fair Ratio model suggests CI's reasonable P/E should be 28.7x.
โ ๏ธ Regulatory scrutiny on pharmacy benefits may pressure CI margins.
๐ Cigna Group has returned approximately 41.0% over the past five years, framing the stock as a steady compounder.
๐ The company currently trades at a P/E ratio of about 11.5x, significantly below the Healthcare industry average of 25.0x and peer average of 31.6x.
๐ A high value score of 6 suggests Cigna Group is broadly checked as cheap relative to where the stock currently trades.
๐ก The Fair Ratio model points to a P/E of 28.7x as a reasonable reference, indicating a wide gap between current multiples and sector benchmarks.
๐ The launch of Connected Benefits aims to support expectations for stronger engagement in Cigna Healthcare products.
โ ๏ธ Ongoing regulatory scrutiny of the pharmacy benefit model can pressure margins and negatively impact investor sentiment.
Bullish Signals
Cigna Group has delivered a solid 41.0% total return over the past five years, establishing it as a steady compounder.
The stock screens as undervalued on market multiples with a high value score of 6, indicating cheapness relative to current trading levels.
Cigna Group trades at a P/E ratio of approximately 11.5x, which is well below the broader Healthcare industry average of 25.0x and peer average of 31.6x.
Risk Factors
Ongoing regulatory scrutiny of its pharmacy benefit model poses a risk that could pressure margins and dampen investor sentiment.
The Cigna Group reported robust second-quarter financial results under new CEO Brian Evanko, posting net income of nearly $1.7 billion ($6.29 per share) and a 7% revenue increase to $71.7 billion. This performance marks the first quarterly report since Evanko took over from David Cordani in July, demonstrating immediate strategic continuity despite industry-wide challenges.
Despite elevated medical costs affecting the broader health insurance sector, Cigna's medical cost ratio rose slightly to 84.5% but remains lower than many competitors facing ratios above 90%. The company attributes part of this increase to prior year risk adjustments in individual plans rather than a fundamental deterioration in its core business operations.
Cigna confidently raised its full-year 2026 earnings outlook to at least $30.45 per share, up from the previous forecast of $30.35. The growth was primarily driven by Cigna Healthcare and Evernorth Health Services, while the company continues to strategically exit lower-margin government-subsidized markets like Medicare Advantage and individual ACA plans.
CEO Brian Evanko emphasized a strategy leveraging technology, data, and artificial intelligence to enhance customer experiences and reduce costs. He stated that these strong results reflect continued progress against their priorities of improving access and lowering costs for patients, validating the effectiveness of their current execution.
๐ Q2 net income rose 8% to $1.66 billion.
๐ฐ Total revenues grew 7% year-over-year to $71.7 billion.
๐ Raised 2026 earnings outlook to at least $30.45 per share.
๐ฅ Medical cost ratio improved to 84.5%, beating rivals.
๐ Exiting government-subsidized markets including ACA plans in 2027.
๐ Cigna reported second-quarter net income of $1.66 billion ($6.29 per share), a significant increase from $1.53 billion in the same period last year.
๐ฐ Total revenues grew 7% year-over-year to reach $71.7 billion, driven by growth in Cigna Healthcare and Evernorth Health Services segments.
๐ The company raised its 2026 earnings outlook to at least $30.45 per share, beating the prior forecast of $30.35 per share.
๐ฅ Medical cost ratio increased to 84.5% in Q2, primarily due to prior year risk adjustments rather than current claim volatility.
๐ Cigna remains competitive with a medical cost ratio significantly lower than rivals exceeding 90% in the industry.
๐ New CEO Brian Evanko is executing a strategy focused on technology and AI to improve customer experiences and operational efficiency.
๐ The company is strategically exiting government-subsidized markets, including the sale of Medicare businesses to HCSC and plans to exit individual ACA plans in 2027.
๐ค This financial report represents the first under the leadership of President and CEO Brian Evanko, who assumed the role on July 1.
Bullish Signals
Net income rose to $1.66 billion.
2026 earnings guidance raised to $30.45 per share.
Revenue increased 7% to $71.7 billion.
Medical cost ratio of 84.5% beats competitors above 90%.
Growth driven by Cigna Healthcare and Evernorth Health Services.
Risk Factors
Medical cost ratio rose to 84.5% from 83.2%.
Elevated medical expenses continue to pressure results.
Bullish Signals
Cigna reported a strong beat with net income rising to $1.66 billion compared to $1.53 billion in the prior year.
The company successfully raised its 2026 earnings guidance to at least $30.45 per share, indicating confidence in future performance.
Revenue increased by 7% to $71.7 billion, demonstrating resilient top-line growth amidst sector headwinds.
Cigna's medical cost ratio of 84.5% is notably lower than many competitors facing ratios above 90%, highlighting a competitive advantage.
Growth was driven by core segments Cigna Healthcare and Evernorth Health Services, validating the company's strategic focus.
Risk Factors
The medical cost ratio rose to 84.5% from 83.2% in the prior year, reflecting continued pressure from elevated medical expenses.
A portion of the increased medical costs is attributed to higher prior year risk adjustments recognized in individual and family plans.
Bradley Foster & Sargent Inc. CT reduced its holdings in Cigna Group (NYSE: CI) by 8.8% during the first quarter, selling 1,747 shares to bring its total position to 18,132 shares valued at $4.837 million. This move contrasts with several other institutional investors who increased their stakes in the fourth quarter, including Assetmark Inc., which added 5,963 shares for a total value of $17.515 million, and apricus wealth LLC, which grew its position by 715.9% to own 9,505 shares worth $2.616 million.
Analyst sentiment regarding Cigna Group remains mixed with varying price targets and ratings from major financial institutions. Sanford C. Bernstein raised its price target to $381.00 with an 'outperform' rating, while Barclays downgraded the stock to 'equal weight' and lowered its objective to $304.00. The consensus average price target stands at $338.80 based on a Moderate Buy rating from MarketBeat data.
Cigna Group recently announced a quarterly dividend of $1.56 per share, payable on September 23rd to stockholders of record as of September 8th, representing a 2.2% yield. Insider trading activity includes CEO David Cordani selling over $59 million in shares under a pre-arranged plan and CAO Jamie G. Kates reducing her position by 27.52%. The company maintains a market capitalization of $76.73 billion with a P/E ratio of 12.30.
๐ Bradley Foster & Sargent Inc. trimmed Cigna holdings by 8.8% to 18,132 shares.
๐ Assetmark Inc. increased position by 10.0% to 65,662 shares valued at $17.5M.
๐ apricus wealth LLC expanded stake by 715.9% to 9,505 shares worth $2.6M.
๐ OFI Invest Asset Management surged 8,357.8% in Q4 with 32,679 shares for $9.1M.
๐ฐ Cigna Group pays $1.56 quarterly dividend with 2.2% yield and Sept 8 ex-date.
๐ Bradley Foster & Sargent Inc. CT trimmed its Cigna Group holdings by 8.8% in Q1, reducing its stake to 18,132 shares valued at $4.837 million.
๐ Assetmark Inc. increased its position by 10.0% to own 65,662 shares worth $17.515 million following a purchase of 5,963 shares in Q1.
๐ apricus wealth LLC expanded its Cigna Group stake by 715.9% in Q4, now holding 9,505 shares valued at $2.616 million.
๐ OFI Invest Asset Management significantly increased its position by 8,357.8% in Q4, acquiring 32,679 shares for a total value of $9.102 million.
๐ฐ Cigna Group announced a quarterly dividend of $1.56 per share with an ex-dividend date of September 8th and a yield of 2.2%.
๐ CEO David Cordani sold 201,878 shares for approximately $59.1 million under a Rule 10b5-1 trading plan on May 12th.
๐ CAO Jamie G. Kates reduced her share count by 27.52% in a transaction worth $268,450 executed on June 12th.
๐ Sanford C. Bernstein raised its price target to $381.00 and maintained an 'outperform' rating in a July 9th report.
โ ๏ธ Barclays downgraded Cigna Group from 'overweight' to 'equal weight' and lowered its price objective to $304.00 on May 26th.
๐ The consensus analyst price target for Cigna Group is $338.80 with an average rating of 'Moderate Buy'.
Bullish Signals
Assetmark Inc. increased stake by 10.0%, buying 5,963 shares.
The article provides a comprehensive overview of The Cigna Group (CI), describing it as a diversified health services company with significant operations in pharmacy benefit management, specialty pharmacy, health insurance, and employer benefits. Its business model focuses on helping employers, government clients, and individuals manage healthcare access, costs, and pharmacy spending, a strategy solidified by its 2018 combination with Express Scripts.
Cigna's core PBM operations involve negotiating drug pricing, managing formularies, processing claims, and providing mail-order services to major institutional clients like the US Department of Defense and health insurers such as Centene. The company also offers medical insurance primarily through employer-sponsored self-funded arrangements where Cigna administers plans while employers bear cost risk.
Financial and technical data indicates that analyst sentiment remains strongly positive, with 87% of analysts rating Cigna a Buy. However, insider selling has been the primary negative factor recently, with net sales of approximately $4.2M over the last 90 days. Technical signals are mixed, showing weakening MACD momentum and neutral RSI, suggesting no clear long-term trend in the near term.
The text concludes by defining various financial metrics such as market cap, P/E ratio, and free cash flow, which are relevant for evaluating Cigna's performance. It notes that while fundamentals are supported by strong analyst ratings, insider activity presents a counterbalancing negative signal for investors considering the stock.
๐ข Cigna operates in pharmacy benefit management, specialty pharmacy, and health insurance.
๐ 87% of analysts rate Cigna as a Buy with strong positive sentiment.
๐ฐ Insiders net sold $4.2M in stock over the last 90 days.
๐ Technical signals weaken as MACD momentum declines and RSI stays neutral.
๐ Specialty pharmacy is critical due to rising drug spending from complex medicines.
๐ข The Cigna Group is a diversified health services company with major operations in pharmacy benefit management, specialty pharmacy, and health insurance.
๐ Analyst sentiment remains strongly positive, with 87% of analysts currently rating Cigna as a Buy.
๐ฐ Insiders were net sellers of approximately $4.2M in Cigna stock over the last 90 days.
๐ Technical signals are weakening in the near term, with MACD momentum declining and RSI remaining neutral.
๐ค Key clients include the US Department of Defense and health insurers like Centene.
๐ Specialty pharmacy is a critical component of Cigna's model due to the growing share of drug spending from complex medicines.
๐ The company operates primarily in the United States with international medical members as well.
๐ก๏ธ Cigna provides self-funded employer coverage where the company administers plans while employers bear cost risk.
๐ Market cap, P/E ratio, and other financial metrics are defined to help investors evaluate the company's valuation.
Bullish Signals
87% of analysts rate Cigna as a Buy.
No rating changes in the last 30 days.
Risk Factors
Insiders sold $4.2M in Cigna stock over last 90 days.
MACD momentum shows technical weakness in near term.
Bullish Signals
Analyst sentiment is strongly positive with 87% of analysts rating Cigna as a Buy.
No rating changes were recorded over the last 30 days, indicating stability in analyst consensus.
Risk Factors
Insiders were net sellers of approximately $4.2M in Cigna stock over the last 90 days.
Technical signals are weakening in the near term with MACD momentum showing a decline.
Allspring Global Investments Holdings LLC significantly reduced its stake in Cigna Group (CI) by 66.3% in the first quarter, selling 185,718 shares and retaining a position worth approximately $25.3 million. While Allspring exited substantially, other institutional investors like apricus wealth LLC, Wealth Enhancement Advisory Services LLC, Nisa Investment Advisors LLC, OFI Invest Asset Management, and Nepsis Inc. increased their holdings in the fourth quarter, collectively maintaining high institutional ownership at 86.99%.
Analyst sentiment remains mixed but generally positive regarding Cigna's financial performance. Raymond James Financial set a $340 target price, while Sanford C. Bernstein raised its target to $381 with an 'outperform' rating. Conversely, Barclays downgraded the stock from 'overweight' to 'equal weight' and lowered its price target to $304. The consensus rating is currently a 'Moderate Buy' with an average price target of $338.80.
Cigna Group reported strong quarterly results for the quarter ended April 30, beating earnings estimates with $7.79 EPS and revenue of $68.52 billion, which was up 4.6% year-over-year. The company also declared a quarterly dividend of $1.56 per share, paid on June 18th to shareholders of record on June 4th, resulting in an annualized dividend yield of 2.2%. CEO David Cordani sold over $59 million in shares under a pre-arranged trading plan, while CAO Jamie Kates sold approximately $268,000 worth of stock.
Financial metrics indicate a stable balance sheet with a debt-to-equity ratio of 0.69 and a market capitalization of $75.13 billion. The stock trades at a P/E ratio of 12.04 and has recently traded between a one-year low of $239.51 and a high of $315.47, currently hovering near its fifty-day moving average of $286.59.
๐ Allspring reduced CI stake by 66.3% to $25.3 million value.
๐ฐ Cigna Q1 EPS hit $7.79 with revenue growth of 4.6%.
๐ต Quarterly dividend declared at $1.56 per share for June 18th.
๐ Barclays downgraded CI from 'overweight' to 'equal weight'.
๐ CEO David Cordani sold shares worth $59.1 million.
๐ Allspring Global Investments Holdings LLC reduced its CI stake by 66.3% in Q1, selling 185,718 shares to retain a position valued at $25.3 million.
๐ Several other institutional investors increased their stakes in Q4, including apricus wealth LLC (+715.9%) and OFI Invest Asset Management (+8,357.8%).
๐ฐ Cigna Group reported Q1 EPS of $7.79, beating the consensus estimate of $7.60, with revenue reaching $68.52 billion.
๐ Revenue grew 4.6% year-over-year to $68.52 billion, demonstrating solid top-line growth for the health services provider.
๐ต The company declared a quarterly dividend of $1.56 per share, paid on June 18th with an annualized yield of 2.2%.
๐ Barclays downgraded CI from 'overweight' to 'equal weight' and lowered its price target from $310 to $304.
๐ฏ Raymond James Financial set a $340 price target, while Sanford C. Bernstein raised its target to $381 with an 'outperform' rating.
๐ CEO David Cordani sold 201,878 shares worth approximately $59.1 million under a pre-arranged Rule 10b5-1 trading plan.
๐ CAO Jamie Kates sold 899 shares for a total transaction value of $268,450.39 on June 12th.
๐ฆ Cigna Group maintains a market cap of $75.13 billion with a P/E ratio of 12.04 and a debt-to-equity ratio of 0.69.
Bullish Signals
Beat EPS estimates at $7.79 vs $7.60 consensus.
Revenue grew 4.6% YoY to $68.52 billion.
Bernstein raised target to $381 with 'outperform' rating.
Raymond James set bullish $340 price target.
Healthy 2.2% dividend yield with 26.45% payout ratio.
Risk Factors
Barclays downgraded stock from 'overweight' to 'equal weight'.
CEO sold 201,878 shares worth over $59 million.
Bullish Signals
Cigna Group beat quarterly earnings estimates, reporting $7.79 EPS compared to the consensus of $7.60.
Revenue increased by 4.6% year-over-year to reach $68.52 billion in the most recent quarter.
Sanford C. Bernstein raised its price target to $381 and assigned an 'outperform' rating on July 9th.
Raymond James Financial set a bullish $340.00 price target for the stock.
The company maintains a healthy dividend yield of 2.2% with a payout ratio of 26.45%.
Institutional ownership remains robust at 86.99%, indicating continued confidence from major funds despite Allspring's reduction.
Risk Factors
Barclys downgraded the stock from 'overweight' to 'equal weight' and lowered its price target from $310 to $304.
CEO David Cordani executed a significant sale of 201,878 shares worth over $59 million, reducing his personal ownership by 85.46%.
California Public Employees Retirement System (CalPERS) reduced its stake in Cigna Group by 7.6% in the first quarter, selling 46,513 shares and holding approximately 0.22% of the company worth $151.7 million. While CalPERS exited a significant portion of its position, several smaller institutional investors and hedge funds increased their holdings during the fourth quarter, including Cary Street Partners, OLD National Bancorp, IHT Wealth Management, Whetstone Capital Advisors, and CYBER HORNET ETFs LLC.
Corporate insiders executed notable stock sales recently. Chief Accounting Officer Jamie G. Kates sold 899 shares for approximately $268,450, reducing his personal stake by 27.5%. More significantly, CEO David Cordani sold 201,878 shares for roughly $59.1 million under a pre-arranged Rule 10b5-1 trading plan, leaving him with an ownership of 34,337 shares representing an 85.46% decrease from his previous position.
Cigna Group reported strong quarterly financial results ending April 30th, beating analyst expectations for both earnings per share and revenue. The company posted $7.79 EPS against a consensus of $7.60 and generated $68.52 billion in revenue versus an estimated $66.29 billion. Revenue grew 4.6% year-over-year, with net margins at 2.26% and a return on equity of 19.75%. The company also paid a quarterly dividend of $1.56 per share to stockholders of record on June 4th.
Analyst sentiment remains generally positive following the earnings beat and strong financial performance. Sanford C. Bernstein raised its price target to $381 with an 'outperform' rating, while Guggenheim, Cantor Fitzgerald, and Wells Fargo also increased their price targets or maintained buy ratings. The consensus price target stands at $338.80, reflecting confidence in the company's growth trajectory and operational efficiency.
๐ CalPERS sold 46,513 shares, retaining a $151.7 million stake.
๐ฐ CEO David Cordani sold 201,878 shares for $59.1 million.
๐ Cigna Group beat Q1 estimates with $7.79 EPS and $68.52B revenue.
๐ต Quarterly dividend of $1.56 yields an annualized 2.2%.
๐ Analysts maintain a 'Moderate Buy' rating with a $338.80 target.
๐ CalPERS trimmed its Cigna Group holdings by 7.6% in Q1, selling 46,513 shares while retaining a stake worth $151.7 million.
๐ Multiple smaller institutional investors increased their stakes in Q4, including Cary Street Partners (+11.0%) and CYBER HORNET ETFs LLC (+5.3%).
๐ฐ CEO David Cordani sold 201,878 shares for $59.1 million under a pre-arranged trading plan, reducing his ownership by 85.46%.
๐ Cigna Group beat Q1 earnings estimates with $7.79 EPS versus the consensus of $7.60 and revenue of $68.52 billion.
๐ Revenue grew 4.6% year-over-year to $68.52 billion, exceeding analyst expectations of $66.29 billion.
๐ต The company paid a quarterly dividend of $1.56 per share, resulting in an annualized yield of 2.2%.
๐ Sanford C. Bernstein raised its price target to $381 and maintained an 'outperform' rating following the earnings report.
๐ The stock achieved a consensus rating of 'Moderate Buy' with a collective analyst price target of $338.80.
๐ Corporate insider ownership dropped to 0.60% following significant sales by the CEO and Chief Accounting Officer.
Bullish Signals
EPS beat estimates at $7.79 vs $7.60 consensus.
Revenue grew 4.6% YoY to $68.52 billion.
Net margin of 2.26% and ROE of 19.75%.
Bernstein raised target to $381 with 'outperform' rating.
Cantor lifted target to $340 with 'overweight' rating.
Risk Factors
CEO David Cordani sold 200,000 shares for $59 million.
CFO Jamie G. Kates decreased stake by 27.5%.
Bullish Signals
Cigna Group reported Q1 earnings of $7.79 per share, beating analyst consensus estimates of $7.60 by $0.19.
Revenue reached $68.52 billion in the quarter, surpassing the expected $66.29 billion and growing 4.6% year-over-year.
The company demonstrated strong profitability with a net margin of 2.26% and a return on equity of 19.75%.
Sanford C. Bernstein increased its price target to $381.00 and reaffirmed an 'outperform' rating on the stock.
Guggenheim raised its price objective to $338.00 and maintained a 'buy' rating for Cigna Group shares.
Cantor Fitzgerald lifted its price target to $340.00 with an 'overweight' rating following recent performance.
Wells Fargo & Company boosted its price target to $305.00 while maintaining an 'equal weight' rating.
The company successfully paid a quarterly dividend of $1.56 per share, indicating healthy cash flow distribution.
Risk Factors
CEO David Cordani significantly reduced his personal stock ownership by selling over 200,000 shares for approximately $59 million.
Chief Accounting Officer Jamie G. Kates sold nearly 900 shares, decreasing his personal stake by 27.5%.
The article provides a comprehensive overview of The Cigna Group (CI), describing it as a diversified health services company with significant operations in pharmacy benefit management, specialty pharmacy, health insurance, and employer benefits. Its business model focuses on helping employers, government clients, and individuals manage healthcare access and costs, a strategy significantly bolstered by its 2018 combination with Express Scripts which established pharmacy benefit management as a central pillar.
Cigna's operations include negotiating drug pricing, managing formularies, processing claims, and providing mail-order services, primarily serving large institutional clients such as the US Department of Defense and health insurers like Centene. The company also offers medical insurance with a strong emphasis on employer-sponsored coverage, often utilizing self-funded arrangements where Cigna administers plans while employers bear cost risk. Its performance is influenced by healthcare utilization trends, prescription drug spending, regulation, and scrutiny of PBM practices.
The text concludes with a technical and analyst sentiment snapshot, noting that 87% of analysts rate the stock as a Buy and that insider selling has been the primary negative factor recently. Technical indicators show the price trading above key moving averages with supportive momentum, though insiders were net sellers of approximately $4.2 million over the last 90 days. The article serves primarily as a fundamental and technical profile rather than reporting on specific recent earnings or news events.
๐ข Cigna Group operates in pharmacy benefit management, health insurance, and employer benefits.
๐ 2018 Express Scripts merger made pharmacy benefit management central to strategy.
๐ค Key clients include US Department of Defense and insurer Centene.
๐ Stock price is above 50-day and 200-day moving averages with bullish signals.
๐ฐ Insiders sold $4.2 million in shares over the last 90 days.
๐ข The Cigna Group is a diversified health services company with major operations in pharmacy benefit management, specialty pharmacy, health insurance, and employer benefits.
๐ Its business scale increased significantly after the 2018 combination with Express Scripts, making pharmacy benefit management central to its strategy.
๐ค Key clients include the US Department of Defense and commercial relationships with insurers like Centene.
๐ Cigna provides medical insurance and benefits primarily in the United States, focusing on employer-sponsored coverage including self-funded arrangements.
๐ Analyst sentiment remains strongly positive with 87% of analysts rating Cigna as a Buy.
๐ Technical signals are described as strongly bullish, with the stock price above both 50-day and 200-day moving averages.
๐ฐ Insider selling is identified as the main negative factor, with net sales of approximately $4.2 million over the last 90 days.
๐ Performance is influenced by healthcare utilization, prescription drug trends, regulation, and scrutiny of PBM practices.
Bullish Signals
87% of analysts rate Cigna as a Buy.
Risk Factors
Insiders sold $4.2M in Cigna stock over last 90 days.
Bullish Signals
Analyst sentiment remains strongly positive with 87% of analysts rating Cigna as a Buy.
Technical indicators are described as strongly bullish, with the stock price trading above both the 50-day and 200-day moving averages.
MACD momentum is supportive and the Relative Strength Index (RSI) is currently showing bullish signals.
Risk Factors
Insider selling is identified as the main negative factor, with insiders being net sellers of approximately $4.2 million in Cigna stock over the last 90 days.
Ascentis Independent Advisors purchased a new stake in Cigna Group (NYSE:CI) totaling 1,964 shares valued at approximately $524,000 during the first quarter. Several other institutional investors also adjusted their positions in the fourth quarter, with Cary Street Partners increasing its stake by 11.0% to own 363 shares worth $100,000, and OLD National Bancorp growing its holdings by 3.7% to reach 1,031 shares valued at $284,000.
Analyst sentiment remains positive with Mizuho raising its price objective from $330.00 to $340.00 and Morgan Stanley increasing its target from $355.00 to $361.00. The consensus price target stands at $338.80 based on a Moderate Buy rating, supported by recent earnings where Cigna reported $7.79 EPS, beating the consensus of $7.60, and revenue of $68.52 billion which exceeded estimates.
Cigna Group recently declared a quarterly dividend of $1.56 per share paid on June 18th to stockholders of record on June 4th, representing an annualized yield of 2.2%. Despite insider sales by CAO Jamie G. Kates and CEO David Cordani under pre-arranged trading plans, the company maintains a market cap of $76.68 billion with a debt-to-equity ratio of 0.69 and has set FY 2026 guidance for EPS between 30.350 and 30.39.
๐ Ascentis Advisors bought 1,964 shares worth $524,000 in Q1.
๐ฆ Cary Street Partners increased stake by 11.0% to own 363 shares.
๐ฐ Cigna reported Q1 EPS of $7.79, beating analyst estimates.
๐ Mizuho raised price objective to $340 with outperform rating.
๐ CEO sold 201,878 shares for $59.1 million under trading plan.
๐ Ascentis Independent Advisors purchased 1,964 shares of Cigna Group valued at approximately $524,000 in the first quarter.
๐ฆ Cary Street Partners increased its stake by 11.0% to own 363 shares worth $100,000 during the fourth quarter.
๐ Mizuho raised its price objective from $330.00 to $340.00 and maintained an outperform rating on Cigna Group.
๐ฐ Cigna reported Q1 EPS of $7.79, topping analyst estimates of $7.60 with revenue of $68.52 billion.
๐ CEO David Cordani sold 201,878 shares for approximately $59.1 million under a Rule 10b5-1 trading plan.
๐ต The company declared a quarterly dividend of $1.56 per share with an annualized yield of 2.2%.
๐ Cigna Group set FY 2026 EPS guidance between 30.350 and 30.39, slightly above analyst predictions.
๐ฅ Cigna operates a global portfolio including medical plans, dental coverage, and pharmacy benefit management.
๐ The stock opened at $289.89 with a 1-year low of $239.51 and a high of $315.47.
๐ Institutional ownership stands at 86.99% across various hedge funds and wealth management firms.
Fideuram Intesa Sanpaolo Private Banking S.P.A. reduced its stake in Cigna Group (NYSE: CI) by 21.6% during the first quarter, selling 2,594 shares to hold a remaining position of 9,411 shares valued at $2.51 million. While this specific fund decreased its exposure, other institutional investors like Pzena Investment Management LLC increased their holdings significantly, adding 7,615 shares to reach a total value of $154.3 million.
Analyst sentiment remains generally positive with several major firms raising price targets or upgrading ratings. Cantor Fitzgerald and Goldman Sachs both raised their price objectives to $340, while Wall Street Zen upgraded the stock to a 'buy' rating. The consensus target price stands at $338.30, suggesting continued institutional confidence in the company's valuation despite mixed hedge fund activity.
Cigna Group reported a quarterly dividend of $1.56 per share paid on June 18th, resulting in an annualized yield of 2.2% and a payout ratio of 26.45%. The stock currently trades at a P/E ratio of 12.19 with a market capitalization of $76.05 billion. Notably, CEO David Cordani sold over $59 million in shares in May under a pre-arranged trading plan, while CAO Jamie G. Kates also reduced her position slightly.
The company operates as a global health services provider offering medical plans, pharmacy benefit management, and supplemental products to commercial, Medicare, and Medicaid customers. Financial metrics indicate a debt-to-equity ratio of 0.69 and a beta of 0.29, reflecting lower volatility compared to the broader market. The stock has traded between $239.51 and $323.10 over the past year.
๐ Fideuram cut Cigna stake by 21.6% to 9,411 shares worth $2.51 million.
๐ Pzena boosted position by 1.3%, adding 7,615 shares valued at $154.3 million.
๐ฆ Cantor Fitzgerald and Goldman Sachs raised price targets to $340 with buy ratings.
๐ฐ Company paid $1.56 quarterly dividend on June 18th for 2.2% annualized yield.
๐ CEO David Cordani sold 201,878 shares for $59.1 million in May under Rule 10b5-1.
๐ Fideuram Intesa Sanpaolo Private Banking S.P.A. cut its Cigna stake by 21.6% in Q1, reducing holdings to 9,411 shares worth $2.51 million.
๐ Pzena Investment Management LLC boosted its position by 1.3%, acquiring an additional 7,615 shares valued at $154.3 million.
๐ฆ Cantor Fitzgerald and Goldman Sachs both raised their price targets to $340 with 'overweight' or 'buy' ratings respectively.
๐ Wall Street Zen upgraded Cigna from a 'hold' to a 'buy' rating in a report dated June 20th.
๐ฐ The company paid a quarterly dividend of $1.56 per share on June 18th, offering a 2.2% annualized yield.
๐ CEO David Cordani sold 201,878 shares for approximately $59.1 million in May under a Rule 10b5-1 trading plan.
๐ The stock trades at a P/E ratio of 12.19 with a market capitalization of $76.05 billion.
๐ Hedge fund ownership stands at 86.99% of the total outstanding shares.
๐ The stock has a fifty-two week range between $239.51 and $323.10 with a current price near $287.50.
๐ฅ Cigna serves commercial, Medicare, and Medicaid customers through medical plans, dental coverage, and pharmacy benefit management.
Bullish Signals
Analysts raised targets to $340 with buy ratings.
2.2% dividend yield with conservative 26.45% payout ratio.
Pzena added over 7,000 shares to stake.
Low beta of 0.29 offers defensive characteristics.
Debt-to-equity ratio is 0.69 with strong liquidity.
Risk Factors
CEO sold $59M shares, reducing stake by 85.46%.
Institutional investor reduced position by 21.6%.
Stock trades below 52-week high of $323.10.
Bullish Signals
Multiple major analysts have raised price targets to $340 or issued 'buy' ratings, indicating strong institutional confidence in the stock's upside potential.
The company maintains a healthy dividend yield of 2.2% with a conservative payout ratio of 26.45%, providing steady income to shareholders.
Pzena Investment Management LLC significantly increased its stake by adding over 7,000 shares, signaling strong institutional accumulation.
Cigna operates with a low beta of 0.29, offering lower volatility and defensive characteristics compared to the broader market.
The company holds a robust balance sheet with a debt-to-equity ratio of 0.69 and maintains liquidity through current and quick ratios of 0.73.
Risk Factors
CEO David Cordani executed a significant sale of over $59 million in shares, reducing his personal stake by 85.46% which may signal reduced insider confidence.
Fideuram Intesa Sanpaolo Private Banking S.P.A. substantially reduced its position by 21.6%, indicating that some institutional investors are trimming exposure.
The stock is currently trading below its fifty-two week high of $323.10 and sits slightly above its fifty-day moving average, suggesting potential consolidation.
Folger Nolan Fleming Douglas Capital Management Inc. acquired a new position in Cigna Group (NYSE:CI) during the first quarter, purchasing 3,521 shares valued at approximately $939,000. Other institutional investors also adjusted their stakes, with Brighton Jones LLC increasing its position by 9.3% to own 3,736 shares and Sivia Capital Partners raising its stake by 10.4%. NewEdge Advisors and the Treasurer of the State of North Carolina also boosted their holdings, while Osterweis Capital Management initiated a new position valued at $163,000.
Several major brokerages have recently issued positive research reports on Cigna Group. Royal Bank Of Canada raised its price target to $337.00 with an 'outperform' rating, while Robert W. Baird and Guggenheim set price objectives at $337.00 and $338.00 respectively, both with 'buy' ratings. UBS Group significantly increased its target from $375.00 to $400.00, maintaining a 'buy' rating, and Wells Fargo raised its target to $305.00. The consensus average price target stands at $338.30 with an overall 'Moderate Buy' rating.
Cigna Group reported strong quarterly earnings on April 30th, beating analyst estimates with EPS of $7.79 against a consensus of $7.60 and revenue of $68.52 billion versus an expected $66.29 billion. The company's revenue grew 4.6% year-over-year, and it has set full-year 2026 guidance for EPS between $30.35 and $30.39, which aligns closely with analyst forecasts of $30.39. Additionally, the firm declared a quarterly dividend of $1.56 per share, paid on June 18th to stockholders of record on June 4th.
๐ Folger Nolan Fleming Douglas Capital acquired 3,521 shares worth $939,000 in Q1.
๐ฐ Cigna reported quarterly EPS of $7.79 and revenue of $68.52 billion, beating estimates.
๐ฏ Full-year 2026 EPS guidance set between $30.35 and $30.39 aligns with forecasts.
๐ต Quarterly dividend declared at $1.56 per share for record holders on June 4th.
๐ CEO David Cordani sold 201,878 shares worth $59.1 million under a trading plan.
๐ Folger Nolan Fleming Douglas Capital Management Inc. acquired a new position in Cigna Group consisting of 3,521 shares valued at approximately $939,000 during the first quarter.
๐ Institutional ownership remains high at 86.99%, with significant increases from Brighton Jones LLC (+9.3%), Sivia Capital Partners (+10.4%), NewEdge Advisors (+4.5%), and the Treasurer of the State of North Carolina (+16.6%).
๐ฆ UBS Group raised its price target on Cigna Group from $375.00 to $400.00 and maintained a 'buy' rating in a research note dated May 22nd.
๐ Royal Bank Of Canada increased its price target to $337.00 with an 'outperform' rating, while Guggenheim raised its objective to $338.00 with a 'buy' rating.
๐ฐ Cigna Group reported quarterly EPS of $7.79, beating analyst estimates of $7.60, and revenue of $68.52 billion, surpassing the expected $66.29 billion.
๐ Revenue for the quarter increased by 4.6% compared to the same period last year, demonstrating consistent growth in the health services sector.
๐ฏ The company set full-year 2026 EPS guidance between $30.35 and $30.39, which aligns closely with analyst forecasts of $30.39.
๐ต Cigna Group declared a quarterly dividend of $1.56 per share, resulting in an annualized dividend yield of 2.2% for stockholders of record on June 4th.
๐ CEO David Cordani sold 201,878 shares valued at approximately $59.1 million under a pre-arranged Rule 10b5-1 trading plan on May 12th.
๐ CAO Jamie G. Kates sold 899 shares valued at approximately $268,450 on June 12th, reducing his personal ownership by 27.52%.
๐ The stock currently trades with a market capitalization of $73.90 billion and a P/E ratio of 11.84, trading above its 200-day moving average of $278.96.
๐ฅ Cigna Group operates as a global health services company offering medical plans, dental/vision coverage, pharmacy benefit management, and supplemental health products.
Bullish Signals
EPS beat at $7.79 vs $7.60 consensus.
Revenue hit $68.52B, up 4.6% year-over-year.
UBS raised target to $400 with 'buy' rating.
Major brokers maintain buy/outperform ratings above current levels.
Full-year 2026 EPS guidance aligns with forecasts.
Healthy 2.2% dividend yield with 26.45% payout ratio.
Risk Factors
CEO sold 201,878 shares ($59.1M), ownership down 85.46%.
CAO sold 899 shares ($268,450), holdings down 27.52%.
Bullish Signals
Cigna Group beat quarterly earnings estimates with EPS of $7.79 versus the consensus of $7.60, indicating strong operational performance.
Revenue for the quarter reached $68.52 billion, exceeding analyst expectations of $66.29 billion and growing 4.6% year-over-year.
UBS Group raised its price target significantly from $375.00 to $400.00 while maintaining a 'buy' rating, signaling strong institutional confidence.
Multiple major brokerages including Royal Bank Of Canada, Robert W. Baird, and Guggenheim issued 'buy' or 'outperform' ratings with price targets above current levels.
The company's full-year 2026 EPS guidance of $30.35-$30.39 aligns closely with analyst forecasts of $30.39, suggesting accurate management forecasting.
Cigna Group maintains a healthy dividend yield of 2.2% with an annualized payout of $6.24 per share and a sustainable payout ratio of 26.45%.
Risk Factors
CEO David Cordani executed a significant sale of 201,878 shares worth approximately $59.1 million, reducing his personal ownership by 85.46%.
CAO Jamie G. Kates sold 899 shares valued at approximately $268,450, representing a 27.52% decrease in his personal stock holdings.
Cigna Corp. (CI) reported first-quarter earnings of $1.18 billion, translating to a profit of $3.68 per share. On an adjusted basis that excludes non-recurring costs and amortization, the company achieved $6.01 per share in earnings.
These financial results significantly exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had projected an average earnings figure of $5.13 per share, while Cigna's actual adjusted performance was substantially higher than this consensus estimate.
The health insurer also posted robust revenue figures for the period. Total revenue reached $44.01 billion, with adjusted revenue coming in at $44.11 billion. Both metrics surpassed the Street forecasts of $43.57 billion set by eight analysts surveyed by Zacks.
Looking ahead to the full year, Cigna provided guidance expecting earnings of $22.60 per share and total revenue of $177 billion. The company's strong quarterly performance and beat of analyst expectations suggest continued financial strength in its core insurance business.
๐ Q1 earnings hit $1.18B, beating Wall Street estimates.
๐ฐ Adjusted EPS reached $6.01 vs $5.13 forecast.
๐ต Total revenue totaled $44.01B, exceeding analyst expectations.
๐ฎ Full-year guidance set at $22.60 EPS and $177B revenue.
๐ Cigna reported first-quarter earnings of $1.18 billion, significantly beating Wall Street estimates.
๐ฐ Adjusted earnings per share reached $6.01, well above the consensus forecast of $5.13.
๐ต Total revenue for the quarter was $44.01 billion, exceeding analyst expectations of $43.57 billion.
๐ Adjusted revenue stood at $44.11 billion, further confirming strong top-line growth.
๐ฎ The company guided for full-year earnings of $22.60 per share and revenue of $177 billion.
๐ข Cigna is headquartered in Bloomfield, Connecticut, operating as a major health insurer.
Bullish Signals
Q1 earnings of $1.18B and EPS of $6.01 beat expectations.
Revenue of $44.01B exceeded analyst forecasts.
Full-year guidance: $22.60 EPS and $177B revenue.
Bullish Signals
Cigna's first-quarter earnings of $1.18 billion and adjusted EPS of $6.01 per share both significantly topped Wall Street expectations.
Revenue of $44.01 billion exceeded analyst forecasts, demonstrating strong top-line performance in the health insurance sector.
The company provided forward-looking guidance for full-year earnings of $22.60 per share and revenue of $177 billion, indicating confidence in future growth.
The Cigna Group (NYSE: CI) is a major player in the healthcare sector with a market capitalization of $73.88 billion. Currently trading at $279.27, the stock has dipped slightly but maintains resilience within its 52-week range of $244.41 to $334.39. Analysts project an average target price of $340.50, suggesting a potential upside of approximately 21.93% from current levels.
Financial metrics indicate strong operational efficiency with revenue growth of 4.60% and earnings per share (EPS) of $24.99. The company boasts an attractive forward P/E ratio of 8.35, a return on equity (ROE) of 16.27%, and robust free cash flow of $6.92 billion. These figures provide flexibility for reinvestment, debt reduction, or dividend payments.
Cigna offers a sustainable dividend yield of 2.23% with a conservative payout ratio of 24.36%. Analyst sentiment is overwhelmingly positive, with 20 out of 24 covering analysts issuing buy ratings and no sell recommendations. The company's dual-segment structure, comprising Evernorth Health Services and Cigna Healthcare, positions it to capitalize on growing demand for comprehensive healthcare solutions.
๐ Analysts project $340.50 target price with 21.93% upside potential.
๐ฐ Revenue grew 4.60% with EPS of $24.99 and $6.92B cash flow.
๐ Forward P/E is 8.35 while ROE stands at 16.27%.
๐ต Sustainable 2.23% dividend yield supported by 24.36% payout ratio.
๐ Analysts project an average target price of $340.50, implying a 21.93% upside potential from the current trading price of $279.27.
๐ฐ The company reports strong financial health with revenue growth of 4.60%, EPS of $24.99, and free cash flow of $6.92 billion.
๐ Valuation appears attractive with a forward P/E ratio of 8.35 and a return on equity (ROE) of 16.27%.
๐ต Cigna offers a sustainable dividend yield of 2.23% backed by a conservative payout ratio of 24.36%.
๐ Analyst sentiment is highly positive with 20 buy ratings and no sell recommendations among the 24 analysts covering the stock.
๐ Technical indicators show the stock hovering near its 50-day moving average with an RSI of 38.02, suggesting potential oversold conditions.
๐ข The company operates through two main segments: Evernorth Health Services and Cigna Healthcare, focusing on pharmacy benefit management and care services.
๐ Founded in 1792 and headquartered in Bloomfield, Connecticut, the group recently rebranded to reflect its global commitment to innovative health solutions.
Bullish Signals
Analysts target $340.50, implying 21.93% upside.
ROE stands at 16.27% with 4.60% revenue growth.
Free cash flow reaches $6.92 billion.
20 of 24 analysts rate it a buy.
Forward P/E is 8.35, suggesting undervaluation.
Dividend yield is 2.23% with a 24.36% payout ratio.
Bullish Signals
Analysts set an average target price of $340.50, indicating a significant 21.93% upside potential from the current stock price.
The company demonstrates strong profitability with a return on equity (ROE) of 16.27% and revenue growth of 4.60%.
Cigna generates impressive free cash flow of $6.92 billion, providing ample liquidity for strategic initiatives and shareholder returns.
Analyst sentiment is overwhelmingly bullish, with 20 out of 24 analysts issuing buy ratings and zero sell recommendations.
The forward P/E ratio of 8.35 suggests the stock may be undervalued relative to its future earnings potential.
Cigna offers a sustainable dividend yield of 2.23% with a low payout ratio of 24.36%, supporting income investors.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)